These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26384305)

  • 1. Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling.
    Kaduwal S; Jeong WJ; Park JC; Lee KH; Lee YM; Jeon SH; Lim YB; Min do S; Choi KY
    Oncotarget; 2015 Oct; 6(32):33091-105. PubMed ID: 26384305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sur8 mediates tumorigenesis and metastasis in colorectal cancer.
    Lee YM; Kaduwal S; Lee KH; Park JC; Jeong WJ; Choi KY
    Exp Mol Med; 2016 Jul; 48(7):e249. PubMed ID: 27469030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shoc2/Sur8 protein regulates neurite outgrowth.
    Leon G; Sanchez-Ruiloba L; Perez-Rodriguez A; Gragera T; Martinez N; Hernandez S; Anta B; Calero O; Garcia-Dominguez CA; Dura LM; Peña-Jimenez D; Castro J; Zarich N; Sanchez-Gomez P; Calero M; Iglesias T; Oliva JL; Rojas JM
    PLoS One; 2014; 9(12):e114837. PubMed ID: 25514808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sur8/Shoc2 involves both inhibition of differentiation and maintenance of self-renewal of neural progenitor cells via modulation of extracellular signal-regulated kinase signaling.
    Moon BS; Kim HY; Kim MY; Yang DH; Lee JM; Cho KW; Jung HS; Choi KY
    Stem Cells; 2011 Feb; 29(2):320-31. PubMed ID: 21732489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
    Choi C; Kwon J; Lim S; Helfman DM
    Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The scaffold protein Shoc2/SUR-8 accelerates the interaction of Ras and Raf.
    Matsunaga-Udagawa R; Fujita Y; Yoshiki S; Terai K; Kamioka Y; Kiyokawa E; Yugi K; Aoki K; Matsuda M
    J Biol Chem; 2010 Mar; 285(10):7818-26. PubMed ID: 20051520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways.
    Matsuoka H; Tsubaki M; Yamazoe Y; Ogaki M; Satou T; Itoh T; Kusunoki T; Nishida S
    Exp Cell Res; 2009 Jul; 315(12):2022-32. PubMed ID: 19393235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity.
    Rodriguez-Viciana P; Oses-Prieto J; Burlingame A; Fried M; McCormick F
    Mol Cell; 2006 Apr; 22(2):217-30. PubMed ID: 16630891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis.
    Jiang K; Sun J; Cheng J; Djeu JY; Wei S; Sebti S
    Mol Cell Biol; 2004 Jun; 24(12):5565-76. PubMed ID: 15169915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway.
    Tsubaki M; Satou T; Itoh T; Imano M; Ogaki M; Yanae M; Nishida S
    Toxicol Appl Pharmacol; 2012 Mar; 259(3):402-10. PubMed ID: 22326785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells.
    Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK
    Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAS and downstream RAF-MEK and PI3K-AKT signaling in neuronal development, function and dysfunction.
    Zhong J
    Biol Chem; 2016 Mar; 397(3):215-22. PubMed ID: 26760308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.
    Henderson V; Smith B; Burton LJ; Randle D; Morris M; Odero-Marah VA
    Cell Adh Migr; 2015; 9(4):255-64. PubMed ID: 26207671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2.
    Choi C; Helfman DM
    Oncogene; 2014 Jul; 33(28):3668-76. PubMed ID: 23995792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DA-Raf-Mediated Suppression of the Ras--ERK Pathway Is Essential for TGF-β1-Induced Epithelial-Mesenchymal Transition in Alveolar Epithelial Type 2 Cells.
    Watanabe-Takano H; Takano K; Hatano M; Tokuhisa T; Endo T
    PLoS One; 2015; 10(5):e0127888. PubMed ID: 25996975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
    Jones GG; Del Río IB; Sari S; Sekerim A; Young LC; Hartig N; Areso Zubiaur I; El-Bahrawy MA; Hynds RE; Lei W; Molina-Arcas M; Downward J; Rodriguez-Viciana P
    Nat Commun; 2019 Jun; 10(1):2532. PubMed ID: 31182717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathway crosstalk between Ras/Raf and PI3K in promotion of M-CSF-induced MEK/ERK-mediated osteoclast survival.
    Bradley EW; Ruan MM; Vrable A; Oursler MJ
    J Cell Biochem; 2008 Jul; 104(4):1439-51. PubMed ID: 18275061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.